Adverse event, n (%) | Placebo-fingolimod 0.5 mg (n = 27) | Placebo-fingolimod 1.25 mga(n = 23) | Continuous fingolimod 0.5 mg (n = 47) | Continuous fingolimod 1.25 mga(n = 46) |
---|---|---|---|---|
Any adverse event | 22 (81.5) | 23 (100) | 35 (74.5) | 41 (89.1) |
Any serious adverse event | 1 (3.7) | 4 (17.4) | 1 (2.1) | 0 (0.0) |
Any adverse event leading to discontinuation of study drug | 5 (18.5) | 3 (13.0) | 2 (4.3) | 0 (0.0) |
Any infection or infestation adverse event | 11 (40.7) | 14 (60.9) | 23 (48.9) | 28 (60.9) |
Most commonly reported adverse events b | ||||
Nasopharyngitis | 7 (25.9) | 7 (30.4) | 16 (34.0) | 19 (41.3) |
Liver function test abnormal | 4 (14.8) | 9 (39.1) | 3 (6.4) | 4 (8.7) |
Leukopenia | 4 (14.8) | 1 (4.3) | 0 (0.0) | 3 (6.5) |
Bradycardia | 0 (0.0) | 3 (13.0) | 0 (0.0) | 0 (0.0) |
Influenza | 0 (0.0) | 3 (13.0) | 0 (0.0) | 2 (4.3) |
Second-degree atrioventricular block | 0 (0.0) | 3 (13.0) | 0 (0.0) | 0 (0.0) |
Headache | 0 (0.0) | 2 (8.7) | 5 (10.6) | 0 (0.0) |
Lymphocyte count decreased | 1 (3.7) | 2 (8.7) | 1 (2.1) | 2 (4.3) |
Lymphopenia | 0 (0.0) | 2 (8.7) | 0 (0.0) | 3 (6.5) |
γ-glutamyltransferase increased | 1 (3.7) | 2 (8.7) | 1 (2.1) | 0 (0.0) |
White blood cell count decreased | 0 (0.0) | 2 (8.7) | 0 (0.0) | 1 (2.2) |
Eczema | 0 (0.0) | 1 (4.3) | 1 (2.1) | 4 (8.7) |
Rash | 2 (7.4) | 1 (4.3) | 1 (2.1) | 0 (0.0) |
Alanine aminotransferase increased | 2 (7.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Blood triglycerides increased | 2 (7.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Dental caries | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (6.5) |
Diarrhea | 1 (3.7) | 0 (0.0) | 2 (4.3) | 3 (6.5) |
Stomatitis | 1 (3.7) | 1 (4.3) | 0 (0.0) | 3 (6.5) |
Pharyngitis | 0 (0.0) | 1 (4.3) | 1 (2.1) | 3 (6.5) |
Tinea pedis | 1 (3.7) | 1 (4.3) | 3 (6.4) | 0 (0.0) |
Skin papilloma | 0 (0.0) | 0 (0.0) | 3 (6.4) | 0 (0.0) |
Serious adverse events | ||||
Bradycardia | 0 (0.0) | 2 (8.7) | 0 (0.0) | 0 (0.0) |
Leukoencephalopathyc | 0 (0.0) | 1 (4.3) | 0 (0.0) | 0 (0.0) |
Multiple sclerosis relapse | 0 (0.0) | 0 (0.0) | 1 (2.1) | 0 (0.0) |
Neuromyelitis optica | 1 (3.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Abortion induced | 0 (0.0) | 1 (4.3) | 0 (0.0) | 0 (0.0) |